Skip to main content

Year: 2021

BW ENERGY: THIRD QUARTER RESULTS 2021

THIRD QUARTER RESULTS 2021 HIGHLIGHTSQ3 EBITDA of USD 8.3 million and net loss of USD 10.3 million No liftings to the Company in the quarter with revenue reflecting approximately 195,000 barrels of quarterly DMO deliveries Q3 gross production of 0.8 million barrels Maintained a strong balance sheet with no debt and cash position of USD 170.6 million Successful completion of Tortue Phase 2 at USD 45 million below budget with the hook-up of production wells DTM-6H and DTM-7H in October Two liftings to the Company scheduled in the fourth quarter Hibiscus/Ruche development activities on track Provisional award of operatorship of two blocks in Gabon’s 12th Offshore Licensing Round Acquired semi-submersible rig for repurposing to unlock Kudu development in NamibiaEBITDA for the third quarter of 2021 was USD 8.3 million, down from USD 46.9...

Continue reading

BW Offshore: Third quarter results 2021

Third quarter results 2021 HIGHLIGHTSEBITDA of USD 97.1 million and operating cashflow of USD 157.2 million Completed Barossa FPSO debt financing and equity joint venture partnership Barossa FPSO project progressing as planned USD 67 million in gross proceeds from block sale of shares in BW Energy in October Quarterly cash dividend of USD 0.035 per share Equity ratio of 39.0% and USD 305.7 million in available liquidity One-year contract extension for FPSO Sendje Berge signed in NovemberIn the third quarter, BW Offshore continued to progress the Barossa FPSO project according to plan, including completing the debt financing and the equity joint venture partnership for the project. First steel cut for the FPSO hull was achieved in September ahead of original schedule. Due to price inflation for materials, the project is experiencing...

Continue reading

Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study

Ad hoc announcement pursuant to Art. 53 LRVamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the good safety and tolerability profile was confirmed Switching from prednisone to vamorolone after week 24 maintained efficacy and improved on multiple safety parameters including restoration of growth trajectory and reduction of behavioral changes up to week 48 Switching from placebo to vamorolone after week 24 resulted in an improvement of multiple efficacy outcome parameters with no apparent increase in the rate of treatment-emergent adverse events (TEAE) up to week 48 Study confirmed good safety and tolerability profile of vamorolone with 98% subjects completing the period from week 24 to week 48Pratteln, Switzerland, and Rockville, MD, USA, November 23, 2021 – Santhera Pharmaceuticals...

Continue reading

Change of Directors at Constellation Software

TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) — The board of directors of Constellation Software Inc. (“Constellation”) (TSX: CSU) announced today the resignation of Steve Scotchmer from, and the appointment of Laurie Schultz to, Constellation’s Board of Directors. Mr. Scotchmer has served on Constellation’s board since 2000. “Steve took what he learned as an operator and helped us weave those lessons into Constellation’s fabric. He took what he learned as an investor and taught us the discipline of permanent ownership. His operating and investing philosophies inspired the creation of Constellation and are infused throughout the organisation. I am fortunate to have had his counsel for the last 35 years,” said Constellation founder and President Mark Leonard. Ms. Schultz has over thirty years of experience in the software and technology...

Continue reading

Vinco Ventures, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2021

Fairport, NY, Nov. 22, 2021 (GLOBE NEWSWIRE) — Vinco Ventures, Inc. (NASDAQ:BBIG), a digital media and content technologies holding company (“Vinco Ventures,” or the “Company”), today announced results for the third quarter ended September 30, 2021. “We are very pleased with our operational developments in the quarter, which included key building blocks of our strategy to create a global media and content platform,” said Lisa King, Chief Executive Officer of Vinco Ventures. “Importantly, through our joint venture, ZVV Media, we completed the acquisition of an 80% interest in Lomotif, a global, pure play video-sharing social networking platform and we are making good progress on extending the brand to additional geographies, including the U.S. and India. We also announced the planned spin-off of our blockchain business, Cryptyde,”...

Continue reading

Jade Power Reports Third Quarter 2021 Results

TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) — Jade Power Trust (“Jade Power” or the “Trust”) (TSXV: JPWR.UN) is pleased to report its third quarter 2021 financial results. All amounts are expressed in Canadian Dollars unless otherwise noted. Highlights1Energy generation of 30,516 MWh for the third quarter of 2021 compared to 34,713 MWh for the third quarter of 2020. Energy generation of 109,898 MWh for the nine months ended September 30, 2021, compared to 123,169 MWh with the comparable period in 2020. Energy generation for the third quarter and for the nine months ended September 30, 2021 was lower than the prior year’s comparable periods primarily due to less favorable wind levels. Revenue of $4.3 million for the third quarter of 2021, compared to $4.5 million for the third quarter of 2020. Revenue...

Continue reading

Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the nine months ended September 30, 2021 and provided a business update. “Adamis made significant advancements over the past year,” stated Dennis J. Carlo, Ph.D., President and Chief Executive Officer of Adamis Pharmaceuticals. “We resubmitted our NDA for ZIMHI to the FDA. We initiated and began enrolling patients in a Phase 2/3 clinical trial to evaluate the use of Tempol for the treatment of COVID-19. Under our new commercial partner, we have seen significant sales growth for SYMJEPI....

Continue reading

Zoom Reports Financial Results for the Third Quarter of Fiscal Year 2022

Third quarter total revenue of $1,050.8 million, up 35% year over year Number of customers contributing more than $100,000 in TTM revenue up 94% year over year Third quarter GAAP operating margin of 27.7% and non-GAAP operating margin of 39.1%SAN JOSE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced financial results for the third fiscal quarter ended October 31, 2021. “In Q3, we held our premier user event, Zoomtopia, on our Zoom Events service. During this immersive, multi-track conference, we showcased how Zoom is placing people at the center of our communications platform, connecting their disparate work streams into our technology, moving beyond enterprises’ ability to collaborate internally, and empowering them to communicate face-to-face with their customers through...

Continue reading

Genasys Inc. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

Achieves Record Revenue of $47 Million and Backlog of $36 Million SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in critical communications systems and solutions that help protect and keep people safe, today announced record fiscal fourth quarter and fiscal year revenue and record fiscal year backlog in its financial results for the fiscal year ended September 30, 2021. “Our fiscal year 2021 was a year of solid performance with a significant level of investment to position us for future growth in our emerging Software as a Service (SaaS) business,” said Richard S. Danforth, Chief Executive Officer of Genasys, Inc. “Our fiscal fourth quarter revenue grew by 8% to $15.0 million, and full-year revenue grew 9% to $47.0 million, continuing our track record of revenue growth over the past five...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.